Skip to search formSkip to main contentSkip to account menu

GS-9451

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinolines

Narrower (1)

vedroprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Vedroprevir in the management of hepatitis C virus infection
ABSTRACT Introduction: Hepatitis C Virus (HCV) is a chronic infection of the liver and the leading cause of liver failure and… 
2017
2017
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
High sustained virologic response (SVR) rates have been observed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir… 
2016
2016
Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach
The hepatitis C virus (HCV), of the family flaviviridae, is one of the major causes of chronic liver diseases. Until the year… 
2015
2015
P0875 : Predictors of sustained viral response to 4–6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/− GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial)
2014
2014
Current race in the development of DAAs (direct-acting antivirals) against HCV.
2013
2013
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… 
2013
2013
13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION
2011
2011
1232 IN VITRO STUDIES ON THE POTENTIAL FOR THE HEPATITIS C VIRUS PROTEASE INHIBITORS GS-9256 AND GS-9451 TO AFFECT BILIRUBIN ELIMINATION
2011
2011
778 PRECLINICAL PROPERTIES OF THE NOVEL HCV NS3 PROTEASE INHIBITOR GS-9451
2011
2011
1248 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF HCV RESISTANCE FROM A MULTIPLE DOSE CLINICAL TRIAL OF GS-9451, A NOVEL NS3 PROTEASE INHIBITOR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)